Skip to main content

Invasive Ductal Carcinoma clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for
  • Xoft® Axxent® eBx® IORT System®

    Sorry, in progress, not accepting new patients

    The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer. Hypothesis: IORT using the Xoft Axxent eBx System is no worse (non-inferior) than whole breast irradiation (WBI) when used as stand-alone radiation treatment in breast conserving therapy in women with early stage breast cancer.

    Los Angeles, California and other locations

Our lead scientists for Invasive Ductal Carcinoma research studies include .

Last updated: